Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-19

Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety, tolerability and efficacy of XEN1101 in major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XEN1101

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED